Celcuity Inc. (NASDAQ:CELC) Receives $30.17 Consensus Price Target from Brokerages

Shares of Celcuity Inc. (NASDAQ:CELC) have received an average recommendation of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $30.17.

CELC has been the subject of a number of recent analyst reports. Needham & Company LLC boosted their price target on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Celcuity in a research report on Friday, November 15th.

Celcuity Price Performance

Shares of NASDAQ:CELC opened at $11.87 on Friday. The company has a 50 day moving average of $12.30 and a 200 day moving average of $14.35. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The stock has a market cap of $440.73 million, a P/E ratio of -4.55 and a beta of 0.73. Celcuity has a 12 month low of $10.35 and a 12 month high of $22.19.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new position in shares of Celcuity in the 3rd quarter worth about $33,000. Prospera Private Wealth LLC bought a new stake in Celcuity in the 3rd quarter worth approximately $35,000. Values First Advisors Inc. purchased a new stake in Celcuity in the third quarter worth approximately $86,000. SG Americas Securities LLC bought a new position in Celcuity during the third quarter valued at approximately $119,000. Finally, Bleakley Financial Group LLC purchased a new position in shares of Celcuity during the fourth quarter worth approximately $146,000. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.